Status:
UNKNOWN
Safety Study of Melatonin in Stroke Patients
Lead Sponsor:
Wolfson Medical Center
Conditions:
Acute Ischemic Stroke
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The purpose of the study is to evaluate the effect of Melatonin (in a dosage of 14mg daily) for a better clinical outcome in the period three days post stroke.
Detailed Description
Stroke is the third most common cause of stroke. The cascade of event is separated into hyperacute,,acute,sub-acute and chronic. In the acute, sub acute state there are mechanisms of inflammation apop...
Eligibility Criteria
Inclusion
- within 72hours of ischemic stroke
- age 18-80
- both gender
- ability to sign consent form
Exclusion
- intra-cerebral bleeding
- tumour of brain
- multiple sclerosis
- s/p craniotomy
- known allergy to melatonin
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT01863277
Start Date
July 1 2013
Last Update
May 27 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
E. Wolfson Medical Center
Holon, Israel, 58100